Spondyloarthropathy 1 (SPDA1)

Categories: Genetic diseases, Rare diseases, Bone diseases

Aliases & Classifications for Spondyloarthropathy 1

MalaCards integrated aliases for Spondyloarthropathy 1:

Name: Spondyloarthropathy 1 57 75 38
Ankylosing Spondylitis 57 38 12 76 53 25 75 37 29 6 43 15 73
Spondyloarthropathy, Susceptibility to, 1 57 13 40
Marie-Strumpell Spondylitis 57 53 75
Bechterew Syndrome 57 53 75
Spondylarthritis Ankylopoietica 25 75
Spondylitis, Ankylosing 25 44
Reiter Syndrome 75 73
Spda1 57 75
Ankylosing Spondylitis, Susceptibility to 57
Spondyloarthritis Ankylopoietica 25
Ankylosing Spondyloarthritis 53
Ankylosing Spondylarthritis 75
Spondylitis Ankylopoietica 25
Marie-Struempell Disease 25
Marie-Strumpell Disease 12
Rheumatoid Spondylitis 75
Spondylitis Ankylosans 75
Spondylitis Ankylosing 55
Spondylarthropathies 73
Arthritis, Psoriatic 73
Psoriatic Arthritis 75
Bekhterev's Disease 12
Arthritis, Reactive 73
Reactive Arthritis 75
Bekhterev Syndrome 12
Bechterew Disease 25
As 25




overall prevalence is between 0.5 and 14 per 100,000 people per year
genetic heterogeneity (see spondyloarthropathy, susceptibility to, 2 )
spondyloarthropathy includes a spectrum of related disorders, including, 1 - ankylosing spondylitis (as), 2 - a subset of psoriatic arthritis (psa), 3 - reactive arthritis (rea), 4 - arthritis associated with inflammatory bowel disease (aibd), 5 - undifferentiated spondyloarthropathy (uspa)


spondyloarthropathy 1:
Inheritance heterogeneous multifactorial inheritance


Summaries for Spondyloarthropathy 1

MedlinePlus : 43 Ankylosing spondylitis is a type of arthritis of the spine. It causes inflammation between your vertebrae, which are the bones that make up your spine, and in the joints between your spine and pelvis. In some people, it can affect other joints. AS is more common and more severe in men. It often runs in families. The cause is unknown, but it is likely that both genes and factors in the environment play a role. Early symptoms of AS include back pain and stiffness. These problems often start in late adolescence or early adulthood. Over time, AS can fuse your vertebrae together, limiting movement. Some people have symptoms that come and go. Others have severe, ongoing pain. A diagnosis of AS is based on your medical history and a physical examination. You may also have imaging or blood tests. AS has no cure, but medicines can relieve symptoms and may keep the disease from getting worse. Eating a healthy diet, not smoking, and exercising can also help. In rare cases, you may need surgery to straighten the spine. NIH: National Institute of Arthritis and Musculoskeletal and Skin Disease

MalaCards based summary : Spondyloarthropathy 1, also known as ankylosing spondylitis, is related to reactive arthritis and brucellosis, and has symptoms including pain, stiffness in the spine and stiffness in the neck. An important gene associated with Spondyloarthropathy 1 is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Antigen processing and presentation and Antirheumatics - DMARDs and biological agents. The drugs Celecoxib and Etanercept have been mentioned in the context of this disorder. Affiliated tissues include Placenta and Umbilical Cord, and related phenotypes are aortic regurgitation and inflammation of the large intestine

Disease Ontology : 12 A bone inflammation disease that results in inflammation in the joints of the spine and pelvis. The disease has symptom pain, has symptom stiffness in the spine, has symptom stiffness in the neck, has symptom stiffness in the hips, has symptom stiffness in the jaw and has symptom stiffness in the rib cage.

Genetics Home Reference : 25 Ankylosing spondylitis is a form of ongoing joint inflammation (chronic inflammatory arthritis) that primarily affects the spine. This condition is characterized by back pain and stiffness that typically appear in adolescence or early adulthood. Over time, back movement gradually becomes limited as the bones of the spine (vertebrae) fuse together. This progressive bony fusion is called ankylosis.

NIH Rare Diseases : 53 Ankylosing spondylitis (AS) is a type of chronic, inflammatory arthritis that mainly affects the spine. It usually begins with inflammation of the joints between the pelvic bones and spine, gradually spreading to the joints between the vertebrae. Signs and symptoms usually begin in adolescence or early adulthood and may include back pain and stiffness. Back movement gradually becomes more limited as the vertebrae fuse together. The condition may also affect the shoulders; ribs; hips; knees; and feet; as well as the eyes; bowel; and very rarely, the heart and lungs. AS is likely caused by a combination of genetic and environmental factors; variations in several genes are thought to affect the risk to develop AS. In most cases, treatment involves exercise and medications to relieve pain and inflammation.

OMIM : 57 Spondyloarthropathy (SpA), one of the commonest chronic rheumatic diseases, includes a spectrum of related disorders comprising the prototype ankylosing spondylitis (AS), a subset of psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthropathy (Miceli-Richard et al., 2004). These phenotypes are difficult to differentiate because they may occur simultaneously or sequentially in the same patient. Studies have suggested that a predominant shared component, including HLA-B27, predisposes to all phenotypic subsets, and that these subsets should be considered as various phenotypic expressions of the same disease (Said-Nahal et al., 2000, Said-Nahal et al., 2001). Braun and Sieper (2007) provided a detailed review of ankylosing spondylitis, including clinical features, pathogenesis, and management. (106300)

UniProtKB/Swiss-Prot : 75 Spondyloarthropathy 1: A chronic rheumatic disease with multifactorial inheritance. It includes a spectrum of related disorders comprising ankylosing spondylitis, a subset of psoriatic arthritis, reactive arthritis (e.g. Reiter syndrome), arthritis associated with inflammatory bowel disease and undifferentiated spondyloarthropathy. These disorders may occur simultaneously or sequentially in the same patient, probably representing various phenotypic expressions of the same disease. Ankylosing spondylitis is the form of rheumatoid arthritis affecting the spine and is considered the prototype of seronegative spondyloarthropathies. It produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints.

Wikipedia : 76 Ankylosing spondylitis (AS) is a type of arthritis in which there is long term inflammation of the... more...

Related Diseases for Spondyloarthropathy 1

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 395)
# Related Disease Score Top Affiliating Genes
1 reactive arthritis 31.1 CD79A CRP HLA-B TNF
2 brucellosis 30.9 CD40LG CRP TNF
3 uveitis 30.7 HLA-B IL17A NOD2 TNF
4 arthritis 30.6 ANKH IL17A MMP3 TNF TNFRSF1B
5 subacute bacterial endocarditis 30.6 CD40LG CD79A
6 familial mediterranean fever 30.6 CRP NOD2 TNF
7 crohn's disease 30.4 CRP NOD2 TNF TNFRSF1B
8 granulomatous dermatitis 30.3 NOD2 TNF
9 aortitis 30.3 CRP MRAP
10 erythema elevatum diutinum 30.2 CD40LG CD79A
11 spondylitis 30.2 CD40LG CRP HLA-B IL17A NOD2 TNF
12 meningitis 30.2 CD40LG CRP TNF
13 iritis 30.0 CD40LG HLA-B MRAP TNFRSF1B
14 purpura 30.0 CD40LG CD79A CRP TNF
15 vasculitis 29.9 CD40LG CD79A CRP TNF TNFRSF1B
16 axial osteomalacia 29.9 BGLAP MRAP
17 ankylosis 29.9 ANKH BGLAP TNFRSF11B
18 chlamydia 29.8 CD40LG CD79A CRP TNF
19 iridocyclitis 29.8 CD40LG HLA-B MRAP
20 hidradenitis suppurativa 29.8 IL17A NOD2 TNF
21 hidradenitis 29.8 IL17A NOD2 TNF
22 demyelinating disease 29.7 CD40LG IL17A TNF
23 spondyloarthropathy 29.7 HLA-B IL17A MMP3 MRAP TNF
24 chorioretinitis 29.6 CD40LG CD79A MRAP
25 takayasu arteritis 29.4 CD40LG CRP HLA-B MMP3 TNF
26 arthropathy 29.3 ANKH CRP TNF TNFRSF11B
27 synovitis 29.3 CRP MMP3 TNF TNFRSF11B
28 rheumatic disease 29.1 CD40LG CRP HLA-B TNF TNFRSF11B
29 systemic lupus erythematosus 28.9 CD40LG CD79A CRP IL17A TNF TNFRSF1B
30 osteoporosis 28.8 BGLAP CRP MMP3 TNF TNFRSF11B
31 autoimmune disease 28.6 CD40LG CD79A HLA-B IL17A TNF TNFRSF1B
32 psoriatic arthritis 27.7 CRP HLA-B IL17A MMP3 NOD2 TNF
33 inflammatory bowel disease 27.7 BGLAP CRP HLA-B IL17A MMP3 NOD2
34 periodontitis 27.7 BGLAP CRP IL17A MMP3 TNF TNFRSF11B
35 rheumatoid arthritis 27.7 CD40LG CD79A CRP HLA-B IL17A MMP3
36 smoking as a quantitative trait locus 3 12.1
37 smoking as a quantitative trait locus 1 11.9
38 smoking as a quantitative trait locus 2 11.9
39 stature as a quantitative trait 11.9
40 angelman syndrome 11.7
41 spinal disease 11.5
42 aortic valve disease 2 11.4
43 systemic onset juvenile idiopathic arthritis 11.2
44 ossification of the posterior longitudinal ligament of spine 11.2
45 temporomandibular ankylosis 11.2
46 microscopic polyangiitis 10.9 HLA-B TNF
47 skin sarcoidosis 10.8 TNF TNFRSF1B
48 intestinal tuberculosis 10.7 CD79A CRP
49 selective igg deficiency disease 10.7 CD40LG CD79A
50 c1q nephropathy 10.7 CD40LG CD79A

Comorbidity relations with Spondyloarthropathy 1 via Phenotypic Disease Network (PDN):

Acute Cystitis Deficiency Anemia
Hypertension, Essential Osteoporosis
Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Spondyloarthropathy 1:

Diseases related to Spondyloarthropathy 1

Symptoms & Phenotypes for Spondyloarthropathy 1

Symptoms via clinical synopsis from OMIM:

Head And Neck Eyes:
anterior uveitis

Abdomen Gastrointestinal:
inflammatory bowel disease (crohns disease and ulcerative colitis)

Skeletal Pelvis:
arthritis (hip)

Skin Nails Hair Skin:

Cardiovascular Heart:
aortic insufficiency
cardiac conduction abnormalities

Skeletal Spine:
accentuated kyphosis
back stiffness
nocturnal back pain
ankylosing spondylitis
Skeletal Limbs:
peripheral arthritis (oligoarticular or polyarticular)
peripheral enthesitis

Laboratory Abnormalities:
hla-b27 haplotype association (95% patients)
rheumatoid factor negative

Clinical features from OMIM:



  • pain
  • stiffness in the spine
  • stiffness in the neck
  • stiffness in the hips
  • stiffness in the jaw
  • stiffness in the rib cage

Human phenotypes related to Spondyloarthropathy 1:

32 (show all 10)
# Description HPO Frequency HPO Source Accession
1 aortic regurgitation 32 HP:0001659
2 inflammation of the large intestine 32 HP:0002037
3 kyphosis 32 HP:0002808
4 back pain 32 HP:0003418
5 psoriasiform dermatitis 32 HP:0003765
6 hip osteoarthritis 32 HP:0008843
7 arrhythmia 32 HP:0011675
8 anterior uveitis 32 HP:0012122
9 sacroiliac arthritis 32 HP:0012317
10 enthesitis 32 HP:0100686

UMLS symptoms related to Spondyloarthropathy 1:

back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Spondyloarthropathy 1:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 ANKH CD40LG CD79A IL17A MMP3 NOD2
2 immune system MP:0005387 9.7 IL17A MMP3 NOD2 TAPBP TNF TNFRSF11B
3 skeleton MP:0005390 9.23 ANKH CD40LG IL17A MMP3 NOD2 TNF

Drugs & Therapeutics for Spondyloarthropathy 1

Drugs for Spondyloarthropathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 185243-69-0
Sulfasalazine Approved Phase 4,Phase 2,Phase 3,Phase 1 599-79-1 5353980 5359476
Adalimumab Approved Phase 4,Phase 2,Phase 3,Not Applicable 331731-18-1 16219006
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
Pamidronate Approved Phase 4,Phase 1,Phase 2 40391-99-9 4674
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
Naproxen Approved, Vet_approved Phase 4,Phase 3 22204-53-1 1302 156391
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
Aceclofenac Approved, Investigational Phase 4 89796-99-6
Acetaminophen Approved Phase 4 103-90-2 1983
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
Hydroxychloroquine Approved Phase 4,Phase 3 118-42-3 3652
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
18 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Not Applicable
21 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 1,Not Applicable
25 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Natriuretic Agents Phase 4
31 Natriuretic Peptide, Brain Phase 4
32 Antacids Phase 4,Phase 3
33 Anti-Ulcer Agents Phase 4,Phase 3
34 Proton Pump Inhibitors Phase 4,Phase 3
35 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
36 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
37 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
39 Vaccines Phase 4,Phase 2
40 Vitamin B Complex Phase 4,Phase 3,Phase 2
41 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Anticholesteremic Agents Phase 4,Not Applicable
45 Cholestyramine Resin Phase 4
46 Hypolipidemic Agents Phase 4,Not Applicable
47 Lipid Regulating Agents Phase 4,Not Applicable
48 Analgesics, Opioid Phase 4
49 Central Nervous System Depressants Phase 4,Phase 3
50 Narcotics Phase 4

Interventional clinical trials:

(show top 50) (show all 370)
# Name Status NCT ID Phase Drugs
1 Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
2 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
3 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
4 Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
5 Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
6 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
7 Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
8 Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
9 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
10 Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
11 A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
12 The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Completed NCT01668004 Phase 4
13 Study Evaluating Etanercept in Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
14 An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
15 Extension Study Evaluating Etanercept in Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
16 Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
17 Infliximab and Methotrexate in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
18 Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis Completed NCT00953979 Phase 4 kunxian capsule
19 Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Completed NCT00715091 Phase 4 diclophenac;diclophenac
20 Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS) Completed NCT01212653 Phase 4 Simponi
21 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study Completed NCT02915354 Phase 4 Etanercept
22 Combination Methotrexate and Infliximab Completed NCT00432432 Phase 4 Infliximab and MTX
23 Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED) Completed NCT00778869 Phase 4
24 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
25 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
26 Tramadol/Acetaminophen(Ultracet) AS add-on Therapy in the Treatment of Patients With Ankylosing Spondylitis Completed NCT00647517 Phase 4 Ultracet
27 Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
28 A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) Completed NCT00779012 Phase 4
29 Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) Completed NCT00779935 Phase 4
30 A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Completed NCT02897115 Phase 4
31 Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
32 Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis Completed NCT01029847 Phase 4 Adalimumab;Placebo
33 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
34 TNFalfa Blocking Treatment of Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
35 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Completed NCT03190603 Phase 4 Celecoxib
36 A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis Completed NCT01298531 Phase 4 etanercept;etanercept;placebo
37 Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis Recruiting NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
38 NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis Recruiting NCT02758782 Phase 4 Celecoxib
39 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylit Recruiting NCT02763046 Phase 4 AIN457/Secukinumab Placebo
40 Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients Recruiting NCT02492217 Phase 4 Adalimumab
41 Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS Recruiting NCT03411798 Phase 4 Yisaipu®
42 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis Recruiting NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
43 Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis Recruiting NCT02634541 Phase 4 Adalimumab
44 Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (MK-8259-038) Recruiting NCT03253796 Phase 4
45 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis Active, not recruiting NCT00573651 Phase 4
46 Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA Active, not recruiting NCT02509026 Phase 4
47 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
48 Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis Not yet recruiting NCT03445845 Phase 4 Secukinumab;TNF blocker
49 An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs) Terminated NCT00766402 Phase 4 Tramadol /acetaminophen;Diclofenac
50 Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients Terminated NCT00910273 Phase 4 etanercept

Search NIH Clinical Center for Spondyloarthropathy 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spondyloarthropathy 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells to treat ankylosing spondylitis
Embryonic/Adult Cultured Cells Related to Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells (family)
Placenta-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: spondylitis, ankylosing

Genetic Tests for Spondyloarthropathy 1

Genetic tests related to Spondyloarthropathy 1:

# Genetic test Affiliating Genes
1 Ankylosing Spondylitis 29 HLA-B

Anatomical Context for Spondyloarthropathy 1

MalaCards organs/tissues related to Spondyloarthropathy 1:

Bone, Testes, Eye, Heart, T Cells, Skin, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spondyloarthropathy 1:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Spondyloarthropathy 1

Articles related to Spondyloarthropathy 1:

(show top 50) (show all 1693)
# Title Authors Year
Association of Long Noncoding RNAs Polymorphisms With Ankylosing Spondylitis, Vogt-Koyanagi-Harada Disease, and Behcet's Disease. ( 29490353 )
Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. ( 29942364 )
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. ( 29945918 )
Recurrent anterior uveitis and subsequent incidence of ankylosing spondylitis: a nationwide cohort study from 2002 to 2013. ( 29415753 )
Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor-I+ antagonists and healthy matched controls. ( 29979389 )
Does the preoperative lumbar sagittal profile affect the selection of osteotomy level in pedicle subtraction osteotomy for thoracolumbar kyphosis secondary to ankylosing spondylitis? ( 29966933 )
Prevalence and factors associated with disturbed sleep in outpatients with ankylosing spondylitis. ( 29971585 )
Characterization of Patients With Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the US-Based Corrona Registry. ( 29409123 )
Associations Between Cardiorespiratory Fitness and Arterial Stiffness in Ankylosing Spondylitis: A Cross-sectional Study. ( 29961684 )
Biomechanical properties of low back myofascial tissue in younger adult ankylosing spondylitis patients and matched healthy control subjects. ( 29936315 )
Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study. ( 29419454 )
Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis : AIP associate with cIMT in AS. ( 29435680 )
Coexistence of Ankylosing Spondylitis and Myotonic Dystrophy: Camptocormia or Thoracic Ankylosis. ( 29465620 )
Identification of ANKDD1B variants in an ankylosing spondylitis pedigree and a sporadic patient. ( 29976160 )
A differential expression network method identifies ankylosing spondylitis-related genes. ( 29970661 )
Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure. ( 29431309 )
TNFAIP3-DEPTOR complex regulates inflammasome secretion through autophagy in ankylosing spondylitis monocytes. ( 29940800 )
Increased Rates of Both Knee and Hip Arthroplasties in Older Patients with Ankylosing Spondylitis. ( 29961693 )
Ankylosing spondylitis kyphosis surgical correction postoperative evaluation via SRS-22 domain investigation. ( 29316959 )
Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). ( 29299630 )
TNF-I+ level affects etanercept clearance: TNF-I+ concentration as a new correction factor of allometric scaling to predict individual etanercept clearances in patients with ankylosing spondylitis. ( 29436715 )
Hepatosplenic T-Cell Lymphoma Arising in a Patient Treated With Tumor Necrosis Factor-I+ Inhibitors for Ankylosing Spondylitis. ( 29933321 )
Pulmonary Sarcoidosis following Etanercept Treatment for Ankylosing Spondylitis: A Case Report and Review of the Literature. ( 29610700 )
Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis. ( 29450863 )
Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin. ( 29967744 )
Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis. ( 29439591 )
A case of ankylosing spondylitis with concurrent Takayasu arteritis. ( 29690806 )
The efficiency of inspiratory muscle training in patients with ankylosing spondylitis. ( 29943207 )
Screening for key genes and transcription factors in ankylosing spondylitis by RNA-Seq. ( 29434723 )
Association of polymorphisms in ERAP1 and risk of ankylosing spondylitis in a Chinese population. ( 29278768 )
MMP-2 silencing reduces the osteogenic transformation of fibroblasts by inhibiting the activation of the BMP/Smad pathway in ankylosing spondylitis. ( 29435070 )
A retrospective study of transcutaneous electrical nerve stimulation for chronic pain following ankylosing spondylitis. ( 29979392 )
Immune cells involved in the pathogenesis of ankylosing spondylitis. ( 29428668 )
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. ( 29667098 )
Bickerstaff brainstem encephalitis in a patient with ankylosing spondylitis on tumour necrosis factor-alpha inhibitor. ( 29465358 )
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. ( 29927479 )
Red Blood Cell Distribution Width in Rheumatoid Arthritis, Ankylosing Spondylitis and Osteoarthritis: True Inflammatory Index or Effect of Anemia? ( 29970432 )
Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography. ( 29415219 )
Complex role of IL-23R polymorphisms on ankylosing spondylitis: a meta-analysis. ( 29944013 )
The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates. ( 29409751 )
Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. ( 29449504 )
Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: A population-based study. ( 29420599 )
The association of HLA-B27 and Klebsiella pneumoniae in ankylosing spondylitis: A systematic review. ( 29438717 )
Translating GWAS in rheumatic disease: approaches to establishing mechanism and function for genetic associations with ankylosing spondylitis. ( 29741584 )
Diffusion-weighted Imaging Is a Sensitive and Specific Magnetic Resonance Sequence in the Diagnosis of Ankylosing Spondylitis. ( 29449501 )
Identification of differential modules in ankylosing spondylitis using systemic module inference and the attract method. ( 29977361 )
Ankylosing Spondylitis Among Familial Mediterranean Fever Patients. ( 28982344 )
Human Leukocyte Antigen C*12:02:02 and Killer Immunoglobulin-Like Receptor 2DL5 are Distinctly Associated with Ankylosing Spondylitis in the Taiwanese. ( 28812990 )
Position 97 of HLA-B, a residue implicated in pathogenesis of ankylosing spondylitis, plays a key role in cell surface free heavy chain expression. ( 27515058 )
Endothelial dysfunction is independent of inflammation and altered CCR7 T cell expression in patients with ankylosing spondylitis. ( 28421995 )

Variations for Spondyloarthropathy 1

ClinVar genetic disease variations for Spondyloarthropathy 1:

# Gene Variation Type Significance SNP ID Assembly Location
1 HLA-B HLA-B, HLA-B27 undetermined variant risk factor

Expression for Spondyloarthropathy 1

Search GEO for disease gene expression data for Spondyloarthropathy 1.

Pathways for Spondyloarthropathy 1

Pathways related to Spondyloarthropathy 1 according to KEGG:

# Name Kegg Source Accession
1 Antigen processing and presentation hsa04612
2 Antirheumatics - DMARDs and biological agents hsamap07050

GO Terms for Spondyloarthropathy 1

Cellular components related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 ANKH CD40LG CD79A HLA-B TNF TNFRSF11B
2 external side of plasma membrane GO:0009897 8.92 CD40LG CD79A IL17A TNF

Biological processes related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.8 IL17A MMP3 TNF TNFRSF1B
2 apoptotic signaling pathway GO:0097190 9.54 TNF TNFRSF11B TNFRSF1B
3 immune response GO:0006955 9.5 CD40LG HLA-B IL17A TAPBP TNF TNFRSF11B
4 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.48 TNF TNFRSF1B
5 regulation of osteoclast differentiation GO:0045670 9.46 BGLAP TNF
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.46 CD40LG TNF TNFRSF11B TNFRSF1B
7 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.43 IL17A NOD2
8 response to inorganic substance GO:0010035 9.4 BGLAP TNFRSF11B
9 negative regulation of lipid storage GO:0010888 9.32 CRP TNF
10 regulation of immunoglobulin secretion GO:0051023 9.26 CD40LG TNF
11 inflammatory response GO:0006954 9.17 CD40LG CRP IL17A NOD2 TNF TNFRSF11B

Molecular functions related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 CD40LG IL17A TNF TNFRSF11B

Sources for Spondyloarthropathy 1

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....